| Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19 RR Razonable, C Pawlowski, JC O'Horo, LL Arndt, R Arndt, DM Bierle, ... EClinicalMedicine 40, 2021 | 130 | 2021 |
| Real-world clinical outcomes of bamlanivimab and casirivimab-imdevimab among high-risk patients with mild to moderate coronavirus disease 2019 R Ganesh, LM Philpot, DM Bierle, RJ Anderson, LL Arndt, RF Arndt, ... The Journal of infectious diseases 224 (8), 1278-1286, 2021 | 88 | 2021 |
| The female-predominant persistent immune dysregulation of the post-COVID syndrome R Ganesh, SL Grach, AK Ghosh, DM Bierle, BR Salonen, NM Collins, ... Mayo Clinic Proceedings 97 (3), 454-464, 2022 | 71 | 2022 |
| Monoclonal antibody therapy for COVID-19 in solid organ transplant recipients ZA Yetmar, E Beam, JC O’Horo, R Ganesh, DM Bierle, L Brumble, ... Open forum infectious diseases 8 (6), ofab255, 2021 | 67 | 2021 |
| Perioperative venous thromboembolism prophylaxis MA Bartlett, KF Mauck, CR Stephenson, R Ganesh, PR Daniels Mayo Clinic Proceedings 95 (12), 2775-2798, 2020 | 67 | 2020 |
| A framework for outpatient infusion of antispike monoclonal antibodies to high-risk patients with mild-to-moderate coronavirus disease-19: the Mayo Clinic model RR Razonable, NCE Aloia, RJ Anderson, G Anil, LL Arndt, RF Arndt, ... Mayo Clinic Proceedings 96 (5), 1250-1261, 2021 | 54 | 2021 |
| Monoclonal antibody treatment of breakthrough COVID-19 in fully vaccinated individuals with high-risk comorbidities DM Bierle, R Ganesh, S Tulledge-Scheitel, SN Hanson, LL Arndt, ... The Journal of Infectious Diseases 225 (4), 598-602, 2022 | 53 | 2022 |
| Telemedicine consultations and follow-up of patients with COVID-19 SJ Crane, R Ganesh, JA Post, NA Jacobson Mayo Clinic Proceedings 95 (9), S33-S34, 2020 | 52 | 2020 |
| Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19 JD Coffey, LA Christopherson, AE Glasgow, KK Pearson, JK Brown, ... npj Digital Medicine 4 (1), 123, 2021 | 51 | 2021 |
| Central sensitization phenotypes in post acute sequelae of SARS-CoV-2 infection (PASC): defining the post COVID syndrome DM Bierle, CA Aakre, SL Grach, BR Salonen, IT Croghan, RT Hurt, ... Journal of primary care & community health 12, 21501327211030826, 2021 | 46 | 2021 |
| Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19 R Ganesh, CF Pawlowski, JC O’Horo, LL Arndt, RF Arndt, SJ Bell, ... The Journal of clinical investigation 131 (19), 2021 | 45* | 2021 |
| Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19 DM Bierle, R Ganesh, CG Wilker, SN Hanson, DE Moehnke, TA Jackson, ... Journal of Primary Care & Community Health 12, 21501327211019282, 2021 | 45 | 2021 |
| Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1. 617.2 (Delta) surge DM Bierle, R Ganesh, RR Razonable Journal of Clinical Virology 145, 105026, 2021 | 39 | 2021 |
| PROMIS scales for assessment of persistent post-COVID symptoms: a cross sectional study R Ganesh, AK Ghosh, MA Nyman, IT Croghan, SL Grach, CV Anstine, ... Journal of Primary Care & Community Health 12, 21501327211030413, 2021 | 32 | 2021 |
| A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID‐19 in skilled care facilities S Tulledge‐Scheitel, SJ Bell, JJ Larsen, DM Bierle, P Takahashi, ... Journal of the American Geriatrics Society 69 (4), 868-873, 2021 | 32 | 2021 |
| Outcomes of COVID-19 with the Mayo Clinic model of care and research JC O’Horo, JR Cerhan, EJ Cahn, PR Bauer, Z Temesgen, J Ebbert, ... Mayo Clinic Proceedings 96 (3), 601-618, 2021 | 32 | 2021 |
| Perioperative evaluation and management of endocrine disorders CP Himes, R Ganesh, EC Wight, V Simha, M Liebow Mayo Clinic Proceedings 95 (12), 2760-2774, 2020 | 32 | 2020 |
| Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild‐to‐moderate coronavirus disease 2019 during the Omicron epoch ZA Yetmar, E Beam, JC O'Horo, MT Seville, L Brumble, R Ganesh, ... Transplant Infectious Disease 24 (4), e13901, 2022 | 30 | 2022 |
| Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the delta variant JC O’Horo, DW Challener, L Speicher, W Bosch, MT Seville, DM Bierle, ... Mayo Clinic Proceedings 97 (2), 327-332, 2022 | 26 | 2022 |
| Clinical prioritization of antispike monoclonal antibody treatment of mild to moderate COVID-19 RR Razonable, R Ganesh, DM Bierle Mayo Clinic Proceedings 97 (1), 26-30, 2022 | 26 | 2022 |
Ryan T. HurtProfessor of Medicine, Mayo ClinicE-mail confirmado em mayo.edu
